Clinical Trial Update: Continuous Dosing of BAY73-4506 in Patients With Advanced Malignancies [Phase 1]

View source ↗

Summary

Phase 1 update on continuous dosing of BAY73-4506 in patients with advanced cancers. The report focuses on safety, tolerability, and preliminary anti-tumor acti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• BAY73-4506 (BAY-73-4506)

Snippet

Sponsor: Bayer | Conditions: Neoplasm | Phase 1 | Status: COMPLETED | Results posted: 2015-01-19